We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
2 own
3 watching
Current Price
$7.33
$-0.34
(-4.43%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
289M
52-Week High
27.46
52-Week Low
7.17
Average Volume
0.14M
Dividend Yield
--
P/E Ratio
--
Market Capitalization289M
52-Week High27.46
52-Week Low7.17
Average Volume0.14M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Stoke Therapeutics, Inc. are pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression. They are developing novel antisense oligonucleotide, or ASO, medicines that target ribonucleic acid, or RNA, and modulate precursor-messenger RNA, or pre-mRNA, splicing to upregulate protein expression where needed and with appropriate specificity to near normal levels. They utilize their proprietary technology platform, Targeted Augmentation of Nuclear Gene Output, or TANGO, to design ASOs to upregulate the expression of protein by individual genes in a patient. Their approach is designed to allow them to deliver in a highly precise, durable and controlled manner disease-modifying therapies to a broad range of relevant tissues, including the central nervous system, or CNS, eye, kidney and liver. They designed their lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. With a well-defined patient population based on routine genetic testing and learnings from recently approved drugs for the treatment of Dravet syndrome to inform the clinical and regulatory pathways for STK-001, they anticipate an efficient clinical program for STK-001. They plan to submit an investigational new drug application, or IND, for STK-001 by early 2020 and expect to initiate a Phase 1/2 clinical trial in the first half of 2020. They intend to nominate a second candidate to treat an additional genetic disease for preclinical development by the first half of 2020. Stoke Therapeutics, Inc. were incorporated under the laws of the State of Delaware in June 2014 under the name ASOthera Pharmaceuticals, Inc. They subsequently changed their name to Stoke Therapeutics, Inc. on May 18, 2016. Their principal executive office is located at 45 Wiggins Avenue, Bedford, Massachusetts, 01730.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
PR Newswire
1month ago
Moore Kuehn, PLLC Encourages Investors of Stoke Therapeutics, Inc. to Contact Law Firm Moore Kuehn, PLLC Encourages Investors of Stoke Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, Oct. 18, 2022 NEW YORK, Oct. 18, 2022 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$7.33
$-0.34
(-4.43%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00